News Home

Where Will Rapt Therapeutics Inc (RAPT) Stock Go Next After It Is Up 34.21% in a Week?

Tuesday, May 17, 2022 04:34 PM | InvestorsObserver Analysts
Where Will Rapt Therapeutics Inc (RAPT) Stock Go Next After It Is Up 34.21% in a Week?

The market has been high on Rapt Therapeutics Inc (RAPT) stock recently. RAPT gets a Bullish score from InvestorsObserver Stock Sentiment Indicator.

Sentiment Score - ,bullish
Rapt Therapeutics Inc has a Bullish sentiment reading. Find out what this means for you and get the rest of the rankings on RAPT!

What is Stock Sentiment?

Sentiment uses short term technical analysis to gauge whether a stock is desired by investors. As a technical indicator, it focuses on recent trends as opposed to the long term health of the underlying company. Updates for the company such as a earnings release can move the stock away from current trends. Changes in price are generally the best indicator of sentiment for a particular stock. At its core, a stock's trend indicates whether current market sentiment is bullish or bearish. Investors must be bullish if a stock is trending upward, and are bearish if a stock is moving down. InvestorsObserver's Sentiment Indicator factors in both price changes and variations in volume. An increase in volume usually means a current trend is stengthening, while a drop in volume tends to signal a reversal to the ongoing trend. Our system also uses the options market in order to receive additional signals on current sentiments. We take into account the ratio of calls and puts for a stock since options allow an investor to bet on future changes in price.

What's Happening With RAPT Stock Today?

Rapt Therapeutics Inc (RAPT) stock is trading at $14.87 as of 4:00 PM on Tuesday, May 17, a gain of $1.12, or 8.15% from the previous closing price of $13.75. The stock has traded between $13.95 and $14.99 so far today. Volume today is 287,588 compared to average volume of 347,312. To see InvestorsObserver's Sentiment Score for Rapt Therapeutics Inc click here.

More About Rapt Therapeutics Inc

RAPT Therapeutics Inc is a clinical-stage immunology-based biopharmaceutical company. It is focused on discovering, developing, and commercializing oral small molecule therapies for patients with significant unmet needs in oncology and inflammatory diseases. The company pipeline products include FLX475, designed to selectively inhibit the migration of immunosuppressive regulatory T cells into tumors; and RPT193, designed to selectively inhibit the migration of type 2 T helper cells into inflamed tissues. Click Here to get the full Stock Report for Rapt Therapeutics Inc stock.

You May Also Like

Get the InvestorsObserver App

InvestorsObserver App
iOS App Android App